These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26325562)

  • 1. Missing Data: How to Best Account for What Is Not Known.
    Newgard CD; Lewis RJ
    JAMA; 2015 Sep; 314(9):940-1. PubMed ID: 26325562
    [No Abstract]   [Full Text] [Related]  

  • 2. Accounting for Missing Data in Clinical Research.
    Stevens JR; Suyundikov A; Slattery ML
    JAMA; 2016 Feb; 315(5):517-8. PubMed ID: 26836740
    [No Abstract]   [Full Text] [Related]  

  • 3. Accounting for Missing Data in Clinical Research--Reply.
    Newgard CD; Lewis RJ
    JAMA; 2016 Feb; 315(5):518. PubMed ID: 26836743
    [No Abstract]   [Full Text] [Related]  

  • 4. Finerenone for Albuminuria in Patients With Diabetic Nephropathy.
    Feng Y; Zeng X; Fu P
    JAMA; 2016 Jan; 315(3):305-6. PubMed ID: 26784783
    [No Abstract]   [Full Text] [Related]  

  • 5. Finerenone for Albuminuria in Patients With Diabetic Nephropathy--Reply.
    Bakris GL; Nowack C
    JAMA; 2016 Jan; 315(3):306. PubMed ID: 26784785
    [No Abstract]   [Full Text] [Related]  

  • 6. Diabetic nephropathy: Nonsteroidal MRA added to RAS blockade reduces albuminuria.
    Weir MR
    Nat Rev Nephrol; 2015 Dec; 11(12):691-2. PubMed ID: 26460357
    [No Abstract]   [Full Text] [Related]  

  • 7. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
    Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
    Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy.
    Jiao XM; Jiao XJ; Zhang XG; Xu XP; Wu JX; Yao L; Zhao J; Lü XF
    Chin Med J (Engl); 2013 Nov; 126(22):4395-6. PubMed ID: 24238537
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiotensin-receptor blockers in the prevention or treatment of microalbuminuria.
    Parfrey PS
    Ann Intern Med; 2009 Jul; 151(1):63-5. PubMed ID: 19581647
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
    Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
    J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
    Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?].
    Lanthier L; Huard G; Plourde MÉ; Cauchon M
    Rev Med Interne; 2020 Jan; 41(1):67-68. PubMed ID: 31812446
    [No Abstract]   [Full Text] [Related]  

  • 14. CCR2 inhibition: a panacea for diabetic kidney disease?
    Weir MR
    Lancet Diabetes Endocrinol; 2015 Sep; 3(9):666-7. PubMed ID: 26268909
    [No Abstract]   [Full Text] [Related]  

  • 15. Adequate vascular repair is relevant to improving renal perfusion and function following vasodilators in normoalbuminuric type 2 diabetic nephropathy.
    Futrakul N; Futrakul P
    Am J Kidney Dis; 2009 Sep; 54(3):583-4. PubMed ID: 19700066
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of breviscapine on urinary micro-albumine in patients with diabetes mellitus type 2].
    Kang SQ; Liu JY
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2003 Jun; 23(6):458-9. PubMed ID: 12872404
    [No Abstract]   [Full Text] [Related]  

  • 17. Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
    Elajami TK; Alfaddagh A; Lakshminarayan D; Soliman M; Chandnani M; Welty FK
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28710178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discounting the efficacy of sulodexide in diabetic nephropathy is premature.
    Gambaro G
    Am J Kidney Dis; 2012 Jul; 60(1):169-70. PubMed ID: 22709598
    [No Abstract]   [Full Text] [Related]  

  • 19. Sulodexide for diabetic nephropathy: another one bites the dust.
    House AA; Weir MA
    Am J Kidney Dis; 2011 Nov; 58(5):692-4. PubMed ID: 22014634
    [No Abstract]   [Full Text] [Related]  

  • 20. Game not over for sulodexide.
    Coccheri S
    Am J Kidney Dis; 2012 Mar; 59(3):467. PubMed ID: 22340910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.